The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Director of BCLC group at IDIBAPS/CIBEREHD; Head of Liver Oncology Unit. Hospital Clinic Barcelona.
Consulting or Advisory Role - AstraZeneca; Bayer; BMS Brazil; Boston Scientific; Engitix Therapeutics; Geneos; Ipsen; Lilly; Merck; Roche; Universal Diagnostics
Speakers' Bureau - AstraZeneca; Bayer; Biotoscana Farma; BMS Brazil; Gilead Sciences; Lilly; Roche
Research Funding - CiberMed; ISCIII
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Ipsen; Lilly; Roche
Other Relationship - Abbvie; Adaptimmune; AstraZeneca; Bayer; Boston Scientific; Bristol Myers Squibb Foundation; Incyte; Ipsen; Medivir; Nerviano Medical Sciences; Roche; TERUMO
Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.
 
Ignacio Melero Bermejo
Honoraria - PharmaMar
Consulting or Advisory Role - Alligator Bioscience; Amunix; AstraZeneca/MedImmune; BiolineRx; Boston Pharmaceuticals; Bright Peak Therapeutics; Bristol-Myers Squibb; Catalym; Curon Biopharmaceutical; Dompé farmaceutici; EMD Serono; F-star; Genmab; Genmab; GlaxoSmithKline; Gossamer Bio; Hookipa Pharma; ImmuneSensor Therapeutics; Merus; Moderna Therapeutics; Monopteros Therapeutics; MSD; Noxxon Pharma; Numab; Pieris Pharmaceuticals; Roche/Genentech; Sanofi; SERVIER; Shattuck Labs
Research Funding - Alligator Bioscience; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche/Genentech
 
Maria J. de Miguel
Honoraria - Janssen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - Abbvie; Array BioPharma; Eisai; Genmab; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Sanofi
 
Guillermo de Velasco
Honoraria - Astellas Pharma; BMS; Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Roche
Research Funding - Ipsen
Travel, Accommodations, Expenses - BMS; BMS; Roche
 
Elena Garralda
Employment - Next Oncology
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Anaveon; Boehringer Ingelheim; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Incyte; Janssen; MAB Discovery; Medscape; Roche; Sanofi; Seagen; Thermo Fisher Scientific
Speakers' Bureau - MSD; Novartis; Roche; Seagen; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Juan Martin-Liberal
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Highlight Therapeutics; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Ipsen; Merck
 
Markus Joerger
Consulting or Advisory Role - AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bristol-Myers Squibb (Inst); Innomedica (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Immunophotonics (Inst); Innomedica (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
 
Guzman Alonso
No Relationships to Disclose
 
Maria-Elisabeth Goebeler
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen-Cilag; Novartis
 
Martin H. Schuler
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; MSD; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; MSD; Novartis; Roche; Sanofi; Tacalyx
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
David König
Honoraria - Amgen; Mirati Therapeutics; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Novartis; PharmaMar
Travel, Accommodations, Expenses - Amgen; Roche; Sanofi
 
Maria Reig
No Relationships to Disclose
 
Maria E. Rodriguez-Ruiz
No Relationships to Disclose
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Jorge Esteban Villarrubia
Employment - Hospital 12 de Octubre
Speakers' Bureau - MSD; Pfizer
 
Paula Sàbat
Travel, Accommodations, Expenses - Gilead Sciences
Other Relationship - Lilly
 
Kira-Lee Koster
Travel, Accommodations, Expenses - Janssen Cilag AG (Inst); Takeda Pharma AG (Inst)
 
Cyrus Sayehli
No Relationships to Disclose
 
Tanja Gromke
No Relationships to Disclose
 
Kathrin Klar
Employment - Catalym
Travel, Accommodations, Expenses - Catalym
 
Eugen Leo
Employment - Catalym
Leadership - Catalym
Stock and Other Ownership Interests - Catalym